SEARCH

SEARCH BY CITATION

References

  • 1
    Querfurth HW & LaFerla FM (2010) Alzheimer’s disease. N Engl J Med 362, 329344.
  • 2
    Hardy J & Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297, 353356.
  • 3
    Hellstrand E, Boland B, Walsh D & Linse S (2010) Amyloid β-protein aggregation produces highly reproducible kinetic data and occurs by a two-phase process. ACS Chem Neurosci 1, 1318.
  • 4
    Klein WL, Krafft GA & Finch CE (2001) Targeting small Aβ oligomers: the solution to an Alzheimer’s disease conundrum? Trends Neurosci 24, 219224.
  • 5
    Jan A, Hartley DM & Lashuel HA (2010) Preparation and characterization of toxic Aβ aggregates for structural and functional studies in Alzheimer’s disease research. Nat Protoc 5, 11861209.
  • 6
    Roychaudhuri R, Yang M, Hoshi MM & Teplow DB (2009) Amyloid β-protein assembly and Alzheimer disease. J Biol Chem 284, 47494753.
  • 7
    Kuperstein I, Broersen K, Benilova I, Rozenski J, Jonckheere W, Debulpaep M, Vandersteen A, Segers-Nolten I, Werf KVD, Subramaniam V et al. (2010) Neurotoxicity of Alzheimer’s disease Aβ peptides is induced by small changes in the Aβ42 to Aβ40 ratio. EMBO J 29, 34083420.
  • 8
    Mawuenyega KG, Sigurdson W, Ovod V, Minsell L, Kasten T, Morris JC, Yarasheski KE & Bateman RJ (2010) Decreased clearance of CNS β-amyloid in Alzheimer’s disease. Science 330, 1774.
  • 9
    Jan A, Adolfsson O, Allaman I, Buccarello A-L, Magistretti PJ, Pfeifer A, Muhs A & Lashuel HA (2011) Aβ42 neurotoxicity is mediated by ongoing nucleated polymerization process rather than by discrete Aβ42 species. J Biol Chem 286, 85858596.
  • 10
    Wogulis M, Wright S, Cunningham D, Chilote T, Powell K & Rydel RE (2005) Nucleation-dependent polymerization is an essential component of amyloid-mediated neuronal cell death. J Neurosci 21, 10711080.
  • 11
    Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, Kilger E, Neuenschwander A, Abramowski D, Frey P, Jaton AL et al. (2006) Exogenous induction of cerebral β-amyloidogenesis is governed by agent and host. Science 313, 17811784.
  • 12
    Barghorn S, Nimmrich V, Striebinger A, Krantz C, Keller P, Janson B, Bahr M, Schmidt M, Bitner RS, Harlan J et al. (2005) Globular amyloid β-peptide1-42 oligomer – a homogenous and stable neuropathological protein in Alzheimer’s disease. J Neurochem 95, 834847.
  • 13
    Kayed R, Pensalfini A, Margol L, Sokolov Y, Sarsoza F, Head E, Hall J & Glabe CG (2009) Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer. J Biol Chem 284, 42304237.
  • 14
    Moore BD, Rangachari V, Tay WM, Milkovic NM & Rosenberry TL (2009) Biophysical analyses of synthetic amyloid-β(1-42) aggregates before and after covalent cross-linking. Implications for deducing the structure of endogenous amyloid-β oligomers. Biochemistry 48, 1179611806.
  • 15
    Ono K, Condron MM & Teplow DB (2009) Structure-neurotoxicity relationships of amyloid β-protein oligomers. Proc Natl Acad Sci USA 106, 1474514750.
  • 16
    O’Nuallain B, Freir DB, Nicoll AJ, Risse E, Ferguson N, Herron CE, Collinge J & Walsh DM (2010) Amyloid β-protein dimers rapidly form stable synaptotoxic protofibrils. J Neurosci 30, 1441114419.
  • 17
    Sandberg A, Luheshi LM, Söllvander S, Barros TPd, Macao B, Knowles TPJ, Biverstål H, Lendel C, Ekholm-Petterson F, Dubnovitsky A et al. (2010) Stabilization of neurotoxic Alzheimer amyloid-β oligomers by protein engineering. Proc Natl Acad Sci USA 107, 1559519600.
  • 18
    Yamaguchi T, Yagi H, Goto Y, Matsuzaki K & Hoshino M (2010) A disulfide-linked amyloid-β peptide dimer forms a protofibril-like oligomer through a distinct pathway from amyloid fibril formation. Biochemistry 49, 71007107.
  • 19
    Yu L, Edalji R, Harlan J, Holzman T, Lopez A, Labkovsky B, Hillen H, Barghorn S, Ebert U, Richardson P et al. (2009) Structural characterization of a soluble amyloid β-peptide oligomer. Biochemistry 48, 18701877.
  • 20
    Müller-Schiffmann A, Andreyeva A, Horn AHC, Gottmann K, Korth C & Sticht H (2011) Molecular engineering of a secreted, highly homogeneous, and neurotoxic Aβ dimer. ACS Chem Neurosci 2, 242248.
  • 21
    Schmechel A, Zentgraf H, Scheuermann S, Fritz G, Pipkorn R, Reed J, Beyreuther K, Bayer TA & Multhaup G (2003) Alzheimer β-amyloid homodimers facilitate Aβ fibrillization and the generation of conformational antibodies. J Biol Chem 278, 3531735324.
  • 22
    Jin M, Shepardson N, Yang T, Chen G, Walsh D & Selkoe DJ (2011) Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosporylation and neuritic degeneration. Proc Natl Acad Sci USA 108, 58195824.
  • 23
    McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI & Masters CL (1999) Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease. Ann Neurol 46, 860866.
  • 24
    Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA et al. (2008) Amyloid-β protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat Med 14, 837842.
  • 25
    Gellermann GP, Byrnes H, Striebinger A, Ullrich K, Mueller R, Hillen H & Barghorn S (2008) Aβ-globulomers are formed independently of the fibril pathway. Neurobiol Dis 30, 212220.
  • 26
    Matsumura S, Shinoda K, Yamada M, Yokojima S, Inoue M, Ohnishi T, Shimada T, Kikuchi K, Masui D, Hashimoto S et al. (2011) Two distinct amyloid β-protein (Aβ) assembly pathways leading to oligomers and fibrils identified by combined fluorescence correlation spectroscopy, morphology and toxicity analyses. J Biol Chem 286, 1155511562.
  • 27
    Noguchi A, Matsumura S, Dezawa M, Tada M, Yanazawa M, Ito A, Akioka M, Kikuchi S, Sato M, Ideno S et al. (2009) Isolation and characterization of patient-derived, toxic, high mass amyloid β-protein (Aβ) assembly from Alzheimer disease brains. J Biol Chem 284, 3289532905.
  • 28
    Walsh DM, Lomakin A, Benedek GB, Condron MM & Teplow DB (1997) Amyloid β-protein fibrillogenesis. Detection of a protofibrillar intermediate. J Biol Chem 272, 2236422372.
  • 29
    Harper JD, Wong SS, Lieber CM & Lansbury PT (1997) Observation of metastable Aβ amyloid protofibrils by atomic force microscopy. Chem Biol 4, 119125.
  • 30
    Lashuel HA, Hartley D, Petre BM, Walz T & Lansbury PT (2002) Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418, 291.
  • 31
    Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, Stenh C, Luthman J, Teplow DB, Younkin SG et al. (2001) The ‘Arctic’ APP mutation (E693G) causes Alzheimer’s disease by enhanced Aβ protofibril formation. Nat Neurosci 4, 887893.
  • 32
    Fukumoto H, Tokuda T, Kasai T, Ishigami N, Hidaka H, Allsop D & Nakagawa M (2010) High-molecular-weight β-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J 24, 27162726.
  • 33
    Mårtensson LG, Karlsson M & Carlsson U (2002) Dramatic stabilization of the native state of human carbonic anhydrase II by an engineered disulfide bond. Biochemistry 41, 1586715875.
  • 34
    Matsumura M, Signor G & Matthews BW (1989) Substantial increase of protein stability by multiple disulphide bonds. Nature 342, 291293.
  • 35
    Eijsink VGH, Bjork A, Gåseidnes S, Sirevåg R, Synstad B, van den Burg B & Vriend G (2004) Rational engineering of enzyme stability. J Biotechnol 113, 105120.
  • 36
    Wahlberg E & Härd T (2006) Conformational stabilization of an engineered binding protein. J Am Chem Soc 128, 76517660.
  • 37
    Shimaoka M, Lu C, Salas A, Xiao T, Takagi J & Springer TA (2002) Stabilizing the integrin aM inserted domain in alternative conformations with a range of engineered disulfide bonds. Proc Natl Acad Sci USA 99, 1673716741.
  • 38
    Pace CN, Grimsley GR, Thomson JA & Barnett BJ (1988) Conformational stability and activity of ribonuclease T1 with zero, one, and two intact disulfide bonds. J Biol Chem 263, 1182011825.
  • 39
    Dombkowski AA (2003) Disulfide by Design™: a computational method for the rational design of disulfide bonds in proteins. Bioinformatics 19, 18521853.
  • 40
    Hoyer W, Grönwall C, Jonsson A, Ståhl S & Härd T (2008) Stabilization of a β-hairpin in monomeric Alzheimer’s amyloid-β peptide inhibits amyloid formation. Proc Natl Acad Sci USA 105, 50995104.
  • 41
    Hoyer W & Härd T (2008) Interaction of Alzheimer’s Aβ peptide with an engineered binding protein – thermodynamics and kinetics of coupled folding-binding. J Mol Biol 378, 398411.
  • 42
    Hou L, Shao H, Zhang Y, Li H, Menon NK, Neuhaus EB, Brewer JM, Byeon IJ, Ray DG, Vitek MP et al. (2004) Solution NMR studies of the Aβ(1-40) and Aβ(1-42) peptides establish that the Met35 oxidation state affects the mechanism of amyloid formation. J Am Chem Soc 126, 19922005.
  • 43
    Lazo ND, Grant MA, Condron MC, Rigby AC & Teplow DB (2005) On the nucleation of amyloid β-protein monomer folding. Protein Sci 14, 15811596.
  • 44
    Mitternacht S, Staneva I, Härd T & Irbäck A (2010) Comparing the folding free-energy landscape of Aβ42 variants with different aggregation properties. Proteins 78, 26002608.
  • 45
    Yang M & Teplow DB (2008) Amyloid β-protein monomer folding: free-energy surfaces reveal alloform-specific differences. J Mol Biol 384, 450464.
  • 46
    Maji SK, Wang L, Greenwald J & Riek R (2009) Structure-activity relationship of amyloid fibrils. FEBS Lett 583, 26102617.
  • 47
    Nelson R, Sawaya MR, Balbirnie M, Madsen AO, Riekel C, Grothe R & Eisenberg D (2005) Structure of the cross-β spine of amyloid-like fibrils. Nature 435, 773778.
  • 48
    Paravastu AK, Leapman RD, Yau W-M & Tycko R (2008) Molecular structural basis for polymorphism in Alzheimer’s β-amyloid fibrils. Proc Natl Acad Sci USA 105, 1834918354.
  • 49
    Sciaretta K, Gordon D, Petkova A, Tycko R & Meredith S (2005) Aβ40-lactam(D23/K28) models a conformation highly favorable for nucleation of amyloid. Biochemistry 44, 60036014.
  • 50
    Knowles TPJ, Waudby CA, Devlin GL, Cohen SIA, Aguzzi A, Vendruscolo M, Terentjev EM, Welland ME & Dobson CM (2009) An analytical solution to the kinetics of breakable filament assembly. Science 326, 15331537.
  • 51
    Nowak MA, Krakauer DC, Klug A & May RM (1998) Prion infection dynamics. Integr Biol (Camb) 1, 315.
  • 52
    Macao B, Hoyer W, Sandberg A, Brorsson A-C, Dobson CM & Härd T (2008) Recombinant amyloid β-peptide production by coexpression with an affibody ligand. BMC Biotechnol 8, 82.
  • 53
    Lord A, Gumucio A, Englund H, Sehlin D, Sundquist VS, Söderberg L, Möller C, Gellerfors P, Lannfelt L, Pettersson FE et al. (2009) An amyloid-β protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer’s disease. Neurobiol Dis 36, 425434.
  • 54
    Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW & Glabe CG (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486489.
  • 55
    Biedler J, Roffler-Tarlov S, Schachner M & Freedman L (1978) Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res 38, 37513757.
  • 56
    Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL et al. (1998) Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95, 64486453.
  • 57
    Bernstein SL, Dupuis NF, Lazo ND, Wyttenbach T, Condron MM, Bitan G, Teplow DB, Shea J-E, Ruotolo BT, Robinson CV et al. (2009) Amyloid-β protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer’s disease. Nat Chem 1, 326331.
  • 58
    Chen Y-R & Glabe CG (2006) Distinct early folding and aggregation properties of Alzheimer amyloid-β peptides Aβ40 and Aβ42: stable trimer or tetramer formation by Aβ42. J Biol Chem 281, 2441424422.
  • 59
    Wirths O, Erck C, Martens H, Harmeier A, Geumann C, Jawhar S, Kumar S, Multhaup G, Walter J, Ingelsson M et al. (2010) Identification of low molecular weight pyroglutamate Aβ oligomers in Alzheimer disease: a novel tool for therapy and diagnosis. J Biol Chem 285, 4151741524.
  • 60
    Petkova AT, Yau W-M & Tycko R (2006) Experimental constraints on quaternary structure in Alzheimer’s β-amyloid fibrils. Biochemistry 45, 498512.
  • 61
    Habicht G, Haupt C, Friedrich RP, Hortschansky P, Sachse C, Meinhardt J, Wieligmann K, Gellermann GP, Brodhun M, Götz J et al. (2007) Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Aβ protofibrils. Proc Natl Acad Sci USA 104, 1923219237.
  • 62
    Cerf E, Sarroukh R, Tamamizu-Kato S, Breydo L, Derclaye S, Dufrêne YF, Narayanaswami V, Goormaghtigh E, Ruysschaert J-M & Raussens V (2009) Antiparallel β-sheet: a signature structure of the oligomeric amyloid β-peptide. Biochem J 421, 415423.